March 14: The FDA granted accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma or those who have relapsed after at least three lines of therapy. The FDA has approved the Merck and Co., Inc. programmed death receptor-1 inhibitor for other cancers. For the most recent […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.